First Malaria Treatment: Mosquirix
- Category
Science & Technology
- Published
14th Oct, 2021
-
Context
World's first Malaria Vaccine has been endorsed recently by the World health Organization.
About
About the Vaccine
- The WHO recommendation is for RTS, S - or Mosquirix - a vaccine developed by British drug maker GlaxoSmithKline.
- The active ingredient in Mosquirix is ??made up of proteins found on the surface of Plasmodium falciparum parasites (PFP).
- RTS, S aims to start the immune system in the early stages of malaria when PFP enters the bloodstream through a mosquito bite and infects liver cells.
- The RTS malaria vaccine, S / AS01 is used to prevent falciparum malaria in children living in regions with moderate to high transmission.
- falciparum, the most common form of malaria in Africa.
- It is the first vaccine and the only one that shows partial protection against young children.
- The malaria vaccine should be given in a 4-dose program to children from five months of age to reduce the incidence of malaria and the burden.
- The vaccine adds to the development of the malaria tool and can help get malaria control back on track.
- It also helps prevent liver infection with the Hepatitis B virus.
Malaria
- Malaria is a life-threatening disease caused by parasites transmitted to humans through the bite of female Anopheles mosquitoes.
- It is preventable and curable.
- Over the past two decades, 11 countries have been WHO-certified free of malaria:
- United Arab Emirates (2007)
- Morocco (2010)
- Turkmenistan (2010)
- Armenia (2011)
- Sri Lanka (2016)
- Kyrgyzstan (2016)
- Paraguay (2018)
- Uzbekistan (2018)
- Algeria (2019)
- Argentina (2019)
- El Salvador (2021)
|